Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study.
Adolescent
Adrenal Cortex Hormones
/ therapeutic use
Antibodies, Viral
/ blood
Betacoronavirus
/ genetics
COVID-19
Child
Child, Preschool
Coronavirus Infections
/ complications
Female
Humans
Immunoglobulins, Intravenous
/ therapeutic use
Male
Nasopharynx
/ virology
Pandemics
Paris
Pneumonia, Viral
/ complications
Prospective Studies
RNA, Viral
/ genetics
SARS-CoV-2
Systemic Inflammatory Response Syndrome
/ drug therapy
Journal
BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488
Informations de publication
Date de publication:
03 06 2020
03 06 2020
Historique:
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
17
6
2020
Statut:
epublish
Résumé
To describe the characteristics of children and adolescents affected by an outbreak of Kawasaki-like multisystem inflammatory syndrome and to evaluate a potential temporal association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Prospective observational study. General paediatric department of a university hospital in Paris, France. 21 children and adolescents (aged ≤18 years) with features of Kawasaki disease who were admitted to hospital between 27 April and 11 May 2020 and followed up until discharge by 15 May 2020. The primary outcomes were clinical and biological data, imaging and echocardiographic findings, treatment, and outcomes. Nasopharyngeal swabs were prospectively tested for SARS-CoV-2 using reverse transcription-polymerase chain reaction (RT-PCR) and blood samples were tested for IgG antibodies to the virus. 21 children and adolescents (median age 7.9 (range 3.7-16.6) years) were admitted with features of Kawasaki disease over a 15 day period, with 12 (57%) of African ancestry. 12 (57%) presented with Kawasaki disease shock syndrome and 16 (76%) with myocarditis. 17 (81%) required intensive care support. All 21 patients had noticeable gastrointestinal symptoms during the early stage of illness and high levels of inflammatory markers. 19 (90%) had evidence of recent SARS-CoV-2 infection (positive RT-PCR result in 8/21, positive IgG antibody detection in 19/21). All 21 patients received intravenous immunoglobulin and 10 (48%) also received corticosteroids. The clinical outcome was favourable in all patients. Moderate coronary artery dilations were detected in 5 (24%) of the patients during hospital stay. By 15 May 2020, after 8 (5-17) days of hospital stay, all patients were discharged home. The ongoing outbreak of Kawasaki-like multisystem inflammatory syndrome among children and adolescents in the Paris area might be related to SARS-CoV-2. In this study an unusually high proportion of the affected children and adolescents had gastrointestinal symptoms, Kawasaki disease shock syndrome, and were of African ancestry.
Identifiants
pubmed: 32493739
doi: 10.1136/bmj.m2094
pmc: PMC7500538
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Antibodies, Viral
0
Immunoglobulins, Intravenous
0
RNA, Viral
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
m2094Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work
Références
Front Pediatr. 2019 Jan 10;6:421
pubmed: 30687686
Intensive Care Med. 2012 May;38(5):872-8
pubmed: 22273753
Pediatrics. 2009 May;123(5):e783-9
pubmed: 19403470
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
JAMA Pediatr. 2020 Apr 22;:
pubmed: 32320004
Pediatr Rheumatol Online J. 2019 Jan 5;17(1):1
pubmed: 30611297
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Yonsei Med J. 2012 Mar;53(2):262-75
pubmed: 22318812
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Pediatr Int. 2019 Apr;61(4):397-403
pubmed: 30786118
Br J Dermatol. 2020 Jul;183(1):71-77
pubmed: 32348545
J Infect Dis. 2005 Feb 15;191(4):499-502
pubmed: 15655771
BMC Pediatr. 2018 Oct 23;18(1):334
pubmed: 30352566
Pediatr Infect Dis J. 2010 Jun;29(6):483-8
pubmed: 20104198
J Eur Acad Dermatol Venereol. 2020 Apr 27;:
pubmed: 32339344
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
J Pediatr. 2018 Nov;202:186-193
pubmed: 30029859
Lancet. 2002 Oct 19;360(9341):1197-202
pubmed: 12401245
Pediatr Infect Dis J. 2009 Jun;28(6):553-4
pubmed: 19504744
Clin Infect Dis. 2005 Sep 1;41(5):e53-6
pubmed: 16080076
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Nature. 2020 Apr;580(7805):571-572
pubmed: 32313159
Pediatrics. 2014 Apr;133(4):e1009-14
pubmed: 24685950
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
J Formos Med Assoc. 2014 Mar;113(3):148-54
pubmed: 24495555
JAMA. 2020 May 19;323(19):1891-1892
pubmed: 32293639
Histopathology. 2012 Dec;61(6):1156-67
pubmed: 23134515
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Pathol Biol (Paris). 2014 Dec;62(6):365-8
pubmed: 25193448
Heart Rhythm. 2020 Sep;17(9):1487-1492
pubmed: 32380288
Korean J Pediatr. 2012 Dec;55(12):470-3
pubmed: 23300502
Front Pediatr. 2019 Dec 19;7:524
pubmed: 31921732
Pediatrics. 2015 Sep;136(3):e609-14
pubmed: 26304824
Hosp Pediatr. 2020 Jun;10(6):537-540
pubmed: 32265235
Arch Pathol Lab Med. 1981 Sep;105(9):470-3
pubmed: 6895017
Pediatr Radiol. 1987;17(5):383-6
pubmed: 3627858
Nucl Med Commun. 1993 Jul;14(7):539-43
pubmed: 8355912